Board of Directors

Leon Chen

OrbiMed

Carol Gallagher

NEA

Steven P. James

President and CEO, Pionyr Immunotherapeutics

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Mike Powell

Sofinnova

Joshua Resnick

SV Health Investors


Leon Chen

OrbiMed

Leon Chen, Ph.D., is a Venture Partner with OrbiMed. Prior to joining OrbiMed, Dr. Chen was the co-founder of KAI Pharmaceuticals where he built the company as the first employee. He held responsibilities in research, intellectual property and business development before Amgen acquired KAI in 2012. He was previously an Entrepreneur in Residence at Venrock and most recently was a Partner at Skyline Ventures where he served on the board of a number of biotech and diagnostic companies. Dr. Chen has a B.A. in Biochemistry from U.C. Berkeley, a Ph.D in Molecular Pharmacology from Stanford and an M.B.A from the Stanford Graduate School of Business.

Carol Gallagher

NEA

Dr. Gallagher joined NEA as a Partner in October, 2014. She is a proven entrepreneur, operator and, more recently, investor with nearly 30 years of experience in commercial, drug development and business development roles at large and small pharmaceutical companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. After the sale of Calistoga Pharmaceuticals, she spent several years serving as an independent director on multiple biopharma company boards before pursuing a career in venture capital. In addition to serving as a director at Pionyr, she currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, Cleave Biosciences and AnaptysBio.

Steven P. James

President and CEO, Pionyr Immunotherapeutics

Steve has over 25 years of biopharma experience and has been involved in building and leading numerous companies. Prior to joining Pionyr in February 2016, he was president, CEO, and a director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president, CEO, and a director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceutials, Ionis Pharmaceuticals, Landec Corporation, and Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently a director of Cascadian Therapeutics, Antiva Biosciences, Allakos Inc., and Chrono Therapeutics and is a trustee of Middlebridge School in Rhode Island.

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function, using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, now FDA approved and widely used for treatment of melanoma and other cancers.

Dr. Krummel’s lab now focuses on figuring out how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.

Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.

Mike Powell

Sofinnova

Mike joined Sofinnova as a General Partner in 1997. He represents Sofinnova as the Chairman of Galera Therapeutics, Checkmate Pharma, and Dauntless Pharmaceuticals. Prior investments include Labrys Biologics (acquired by Teva) and Intellikine (acquired by Millennium/Takeda). Mike was the initial investor in Actelion (ATLN), InterMune (ITMN), Orexigen Therapeutics (OREX), Seattle Genetics (SGEN), Threshold Pharmaceuticals (THLD), and Trius Therapeutics (TSRX). Before joining Sofinnova, Mike was Group Leader of Drug Delivery at Genentech (1990–97) where his focus was developing new formulations for protein and peptide therapeutics. Mike was the first scientist from the biotechnology industry to be honored as a Fellow of the American Association of Pharmaceutical Scientists.

Mike received his PhD in Physical Chemistry from the University of Toronto and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981–84). He currently serves on the Washington University Board of Trustees in St. Louis. He is also an Adjunct Professor of Pharmaceutical Chemistry at the University of Kansas, and past Editorial Board member of J. Pharm. Sci., and a past Scientific Advisor to the Controlled Release Society.

Joshua Resnick

SV Health Investors

Dr. Resnick is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SV Health Investors, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women’s Hospital, and an Instructor in Medicine at Harvard Medical School.

Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business.